Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Biomolecules ; 11(2)2021 01 26.
Artículo en Inglés | MEDLINE | ID: mdl-33530569

RESUMEN

Ulcerative colitis (UC), one of the two main types of inflammatory bowel disease, has no effective treatment. Rosmarinic acid (RA) is a polyphenol that, when administered orally, is metabolised in the small intestine, compromising its beneficial effects. We used chitosan/nutriose-coated niosomes loaded with RA to protect RA from gastric degradation and target the colon and evaluated their effect on acute colitis induced by 4% dextran sodium sulphate (DSS) for seven days in mice. RA-loaded nanovesicles (5, 10 and 20 mg/kg) or free RA (20 mg/kg) were orally administered from three days prior to colitis induction and during days 1, 3, 5 and 7 of DSS administration. RA-loaded nanovesicles improved body weight loss and disease activity index as well as increased mucus production and decreased myeloperoxidase activity and TNF-α production. Moreover, RA-loaded nanovesicles downregulated protein expression of inflammasome components such as NLR family pyrin domain-containing 3 (NLRP3), adaptor protein (ASC) and caspase-1, and the consequent reduction of IL-1ß levels. Furthermore, nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase-1 (HO-1) protein expression increased after the RA-loaded nanovesicles treatment However, these mechanistic changes were not detected with the RA-free treatment. Our findings suggest that the use of chitosan/nutriose-coated niosomes to increase RA local bioavailability could be a promising nutraceutical strategy for oral colon-targeted UC therapy.


Asunto(s)
Cinamatos/química , Colitis/metabolismo , Depsidos/química , Inflamasomas/metabolismo , Proteína con Dominio Pirina 3 de la Familia NLR/metabolismo , Nanomedicina/métodos , Nanopartículas/química , Animales , Modelos Animales de Enfermedad , Hemo-Oxigenasa 1/metabolismo , Técnicas In Vitro , Inflamación , Masculino , Proteínas de la Membrana/metabolismo , Ratones , Ratones Endogámicos C57BL , Factor 2 Relacionado con NF-E2/metabolismo , Estrés Oxidativo , Peroxidasa/metabolismo , Transducción de Señal , Factor de Necrosis Tumoral alfa/metabolismo , Ácido Rosmarínico
2.
Nutrients ; 12(6)2020 Jun 11.
Artículo en Inglés | MEDLINE | ID: mdl-32545398

RESUMEN

Nutraceuticals include a wide variety of bioactive compounds, such as polyphenols, which have been highlighted for their remarkable health benefits. Specially, maqui berries have shown great antioxidant activity and anti-inflammatory effects on some inflammatory diseases. The objectives of the present study were to explore the therapeutic effects of maqui berries on acute-phase inflammation in Crohn's disease. Balb/c mice were exposed to 2,4,6-trinitrobenzene sulfonic acid (TNBS) via intracolonic administration. Polyphenolic maqui extract (Ach) was administered orally daily for 4 days after TNBS induction (Curative Group), and for 7 days prior to the TNBS induction until sacrifice (Preventive Group). Our results showed that both preventive and curative Ach administration inhibited body weight loss and colon shortening, and attenuated the macroscopic and microscopic damage signs, as well as significantly reducing transmural inflammation and boosting the recovery of the mucosal architecture and its muco-secretory function. Additionally, Ach promotes macrophage polarization to the M2 phenotype and was capable of down-regulating significantly the expression of inflammatory proteins COX-2 and iNOS, and at the same time it regulates the antioxidant Nrf-2/HO-1 pathway. In conclusion, this is the first study in which it is demonstrated that the properties of Ach as could be used as a preventive and curative treatment in Crohn's disease.


Asunto(s)
Antiinflamatorios , Antioxidantes , Enfermedad de Crohn/inducido químicamente , Enfermedad de Crohn/terapia , Suplementos Dietéticos , Frutas/química , Hemo-Oxigenasa 1/metabolismo , Proteínas de la Membrana/metabolismo , Factor 2 Relacionado con NF-E2/metabolismo , Fenómenos Fisiológicos de la Nutrición/fisiología , Fitoterapia , Polifenoles/farmacología , Polifenoles/uso terapéutico , Transducción de Señal/efectos de los fármacos , Ácido Trinitrobencenosulfónico/efectos adversos , Reacción de Fase Aguda , Administración Oral , Animales , Enfermedad de Crohn/genética , Enfermedad de Crohn/prevención & control , Ciclooxigenasa 2/metabolismo , Modelos Animales de Enfermedad , Mediadores de Inflamación/metabolismo , Masculino , Ratones Endogámicos BALB C , Óxido Nítrico Sintasa de Tipo II/metabolismo , Polifenoles/administración & dosificación , Polifenoles/aislamiento & purificación , Transducción de Señal/genética
3.
Eur J Pharmacol ; 797: 75-82, 2017 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-28099869

RESUMEN

Amitriptyline, a tricyclic antidepressant, has been proposed as an antitumoral drug in oxidative therapy. Its pro-apoptotic effects, mediated by high reactive oxygen species generation, have been already described. In this study we analysed the effect of amitriptyline on the biosynthesis of coenzyme Q10 (CoQ), an essential component for electron transport and a potent membrane antioxidant involved in redox signaling. We treated H460 cells, a non-small-cell lung cancer cell line, with amitriptyline and we analysed CoQ levels by HPLC and CoQ biosynthesis rate, as well as the enzymes involved in CoQ biosynthesis by real-time PCR and Western blot. Amitriptyline treatment induced a dose-dependent decrease in CoQ levels in tumor cells. CoQ decreased levels were associated with down-regulation of the expression of COQ4 gene, as well as decreased Coq4 and Coq6 protein levels. Our findings suggest that the effect of amitriptyline on CoQ biosynthesis highlights the potential of this drug for antitumoral oxidative therapy.


Asunto(s)
Amitriptilina/farmacología , Neoplasias Pulmonares/patología , Ubiquinona/análogos & derivados , Línea Celular Tumoral , Relación Dosis-Respuesta a Droga , Humanos , Cinética , Especies Reactivas de Oxígeno/metabolismo , Ubiquinona/biosíntesis , Ubiquinona/metabolismo
4.
Fertil Steril ; 97(5): 1213-9, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22424618

RESUMEN

OBJECTIVE: To investigate the presence of neurokinin B (NKB)/NK(3) receptor (NK(3)R) and kisspeptin/KISS1 receptor (KISS1R) messenger RNA (mRNA) and proteins throughout the human female genital tract. DESIGN: In vitro study. SETTING: Academic research laboratories and academic hospitals. PATIENT(S): Fifteen reproductive-age women and 16 postmenopausal women provided fresh samples of uterus, ovary, or oviduct, and 12 women provided archival samples of endometrium or oviduct. INTERVENTION(S): Fresh and archival samples of uterus, ovary, and oviduct obtained from reproductive-age and postmenopausal women. MAIN OUTCOME MEASURE(S): Results of reverse-transcription polymerase chain reaction (RT-PCR) and immunohistochemistry to investigate the pattern of expression of NKB/NK(3)R and kisspeptin/KISS1R in target tissues. RESULT(S): Expression of the genes encoding NKB (TAC3) and NK(3)R (TACR3), and kisspeptin (KISS1) and its receptor (KISS1R) was found in the uterus, ovary, and oviduct. Both NKB and NK(3)R immunoreactivity was detected in the endometrium, the oviduct, and the ovary, with marked expression in endometrial and oviductal epithelial cells, where intense coexpression of kisspeptin and KISS1R was also detected. Positive staining for NKB and NK(3)R was found in the myometrium where, in contrast, kisspeptin and KISS1R were absent. CONCLUSION(S): NKB/NK(3)R and kisspeptin/KISS1R are present in female peripheral reproductive tissues with colocalization of both systems in some non-neuronal cell populations of the human female genital tract. Our findings are compatible with a potential modulatory role of NKB and kisspeptin at peripheral reproductive tissues.


Asunto(s)
Trompas Uterinas/química , Kisspeptinas/análisis , Neuroquinina B/análisis , Ovario/química , Receptores Acoplados a Proteínas G/análisis , Receptores de Neuroquinina-3/análisis , Útero/química , Endometrio/química , Femenino , Humanos , Inmunohistoquímica , Kisspeptinas/genética , Neuroquinina B/genética , Posmenopausia , ARN Mensajero/análisis , Receptores Acoplados a Proteínas G/genética , Receptores de Kisspeptina-1 , Receptores de Neuroquinina-3/genética , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Maduración Sexual
5.
J Pineal Res ; 51(1): 44-60, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21752096

RESUMEN

In intestinal bowel disease (IBD), immune-mediated conditions exert their effects through various cells and proinflammatory mediators. Recent data support a participation of the endoplasmic reticulum stress and mitochondrial dysfunctions in IBD. Moreover, it is evident that chronic degenerative pathologies, including IBD, share comparable disease mechanisms with alteration in the autophagy mechanisms. Chronic inflammation in IBD exposes these patients to a number of signals known to have tumorigenic effects. This circuitry of inflammation and cancer modifies apoptosis and autophagy, and promotes cellular cycle progression, invasion, and angiogenesis. Melatonin has been shown as a specific antioxidant reducing oxidative damage in both lipid and aqueous cell environments. However, several studies provide further insight into the molecular mechanisms of melatonin action in the colon. In this line, recent data suggest that melatonin modulates autophagy and sirtuin activity. An anti-autophagic property of melatonin has been demonstrated, and it could contribute to its anti-oncogenic activity. Nevertheless, there is no information about whether antitumoral effects of melatonin on colon cancer are dependent on autophagy. Sirtuins have pleiotropic effects on cancer development, being reported both as facilitator and as suppressor of colon cancer development. Sirtuins and melatonin are connected through the circadian clock machinery, and melatonin seems able to correct the alterations in sirtuin activity associated with several pathological conditions. Autophagy and sirtuin activities are linked through 5'AMP-activated protein kinase (AMPK) activation, which switches on autophagy and increases sirtuin. The effect of melatonin on AMPK and the impact of this effect on IBD and colon cancer remain an open question.


Asunto(s)
Neoplasias del Colon/metabolismo , Enfermedades Inflamatorias del Intestino/metabolismo , Melatonina/metabolismo , Animales , Autofagia/fisiología , Enfermedad Crónica , Neoplasias del Colon/patología , Humanos , Enfermedades Inflamatorias del Intestino/patología
6.
Toxicol Lett ; 204(1): 32-7, 2011 Jul 04.
Artículo en Inglés | MEDLINE | ID: mdl-21501668

RESUMEN

Amitriptyline is a tricyclic antidepressant commonly prescribed for the treatment of several neuropathic and inflammatory illnesses. We have already reported that amitriptyline has cytotoxic effect in human cell cultures, increasing oxidative stress, and decreasing growth rate and mitochondrial activity. Coenzyme Q (CoQ), a component of the respiratory chain and a potent antioxidant, has been proposed as a mitochondrial dysfunction marker. In the present work we evaluated lipid peroxidation, a consequence of oxidative stress, and CoQ level in liver, lung, kidney, brain, heart, skeletal muscle, and serum of mice treated with amitriptyline for two weeks. Lipid peroxidation was increased in a dose-dependent manner in all tissues analyzed. CoQ levels were increased in brain, heart, skeletal muscle, and serum, and strongly decreased in liver and lung. The relation between amitriptyline, CoQ, and oxidative stress is discussed.


Asunto(s)
Amitriptilina/efectos adversos , Antidepresivos Tricíclicos/efectos adversos , Hígado/efectos de los fármacos , Pulmón/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Ubiquinona/deficiencia , Amitriptilina/farmacología , Animales , Antidepresivos Tricíclicos/farmacología , Peroxidación de Lípido/efectos de los fármacos , Hígado/patología , Pulmón/patología , Masculino , Ratones , Ratones Endogámicos C57BL , Ubiquinona/análisis , Ubiquinona/efectos de los fármacos
7.
Endocr Pathol ; 22(1): 35-9, 2011 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-21234707

RESUMEN

It is widely held that solid cell nests (SCN) of the thyroid are ultimobranchial body remnants. SCNs are composed of main cells and C cells. It has been suggested that main cells might be pluripotent cells contributing to the histogenesis of C cells and follicular cells, as well as to the formation of certain thyroid tumors. The present study sought to analyze the immunohistochemical profile of SCN and to investigate the potential stem cell role of SCN main cells. Tissue sections from ten cases of nodular hyperplasia (non-tumor goiter) with SCNs were retrieved from the files of the Hospital Infanta Luisa (Seville, Spain). Parathormone (PTH), calcitonin (CT), thyroglobulin (TG), thyroid transcription factor (TTF-1), galectin 3 (GAL3), cytokeratin 19 (CK 19), p63, bcl-2, OCT4, and SALL4 expression were evaluated by immunohistochemistry. Patient clinical data were collected, and tissue sections were stained with hematoxylin-eosin for histological examination. Most cells stained negative for PTH, CT, TG, and TTF-1. Some cells staining positive for TTF-1 and CT required discussion. However, bcl-2, p63, GAL3, and CK 19 protein expression was detected in main cells. OCT4 protein expression was detected in only two cases, and SALL4 expression in none. Positive staining for bcl-2 and p63, and negative staining for PTH, CT, and TG in SCN main cells are both consistent with the widely accepted minimalist definition of stem cells, thus supporting the hypothesis that they may play a stem cell role in the thyroid gland, although further research will be required into stem cell markers. Furthermore, p63 and GAL-3 staining provides a much more sensitive means of detecting SCNs than staining for carcinoembryonic antigen, calcitonin, or other markers; this may help to distinguish SCNs from their mimics.


Asunto(s)
Células Madre/patología , Nódulo Tiroideo/patología , Adulto , Anciano , Biomarcadores/metabolismo , Femenino , Galectina 3/metabolismo , Humanos , Inmunohistoquímica , Masculino , Persona de Mediana Edad , Células Madre/metabolismo , Nódulo Tiroideo/metabolismo , Transactivadores/metabolismo , Factores de Transcripción , Proteínas Supresoras de Tumor/metabolismo
8.
Anticancer Drugs ; 21(10): 932-44, 2010 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-20847644

RESUMEN

Oxidative therapy is a relatively new anticancer strategy based on the induction of high levels of oxidative stress, achieved by increasing intracellular reactive oxygen species (ROS) and/or by depleting the protective antioxidant machinery of tumor cells. We focused our investigations on the antitumoral potential of amitriptyline in three human tumor cell lines: H460 (lung cancer), HeLa (cervical cancer), and HepG2 (hepatoma); comparing the cytotoxic effect of amitriptyline with three commonly used chemotherapeutic drugs: camptothecin, doxorubicin, and methotrexate. We evaluated apoptosis, ROS production, mitochondrial mass and activity, and antioxidant defenses of tumor cells. Our results show that amitriptyline produces the highest cellular damage, inducing high levels of ROS followed by irreversible serious mitochondrial damage. Interestingly, an unexpected decrease in antioxidant machinery was observed only for amitriptyline. In conclusion, based on the capacity of generating ROS and inhibiting antioxidants in tumor cells, amitriptyline emerges as a promising new drug to be tested for anticancer therapy.


Asunto(s)
Amitriptilina/farmacología , Carcinoma Hepatocelular/terapia , Carcinoma de Pulmón de Células no Pequeñas/terapia , Neoplasias Hepáticas/terapia , Neoplasias Pulmonares/terapia , Oxidantes/farmacología , Estrés Oxidativo/efectos de los fármacos , Neoplasias del Cuello Uterino/terapia , Animales , Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Carcinoma Hepatocelular/metabolismo , Carcinoma Hepatocelular/patología , Carcinoma de Pulmón de Células no Pequeñas/metabolismo , Carcinoma de Pulmón de Células no Pequeñas/patología , Citotoxinas/farmacología , Reposicionamiento de Medicamentos , Femenino , Citometría de Flujo , Células HeLa , Humanos , Neoplasias Hepáticas/metabolismo , Neoplasias Hepáticas/patología , Neoplasias Pulmonares/metabolismo , Neoplasias Pulmonares/patología , Ratones , Mitocondrias/efectos de los fármacos , Mitocondrias/fisiología , Especificidad de Órganos , Oxidación-Reducción/efectos de los fármacos , Especies Reactivas de Oxígeno/análisis , Neoplasias del Cuello Uterino/metabolismo , Neoplasias del Cuello Uterino/patología
9.
Eur J Pharmacol ; 505(1-3): 187-94, 2004 Nov 28.
Artículo en Inglés | MEDLINE | ID: mdl-15556152

RESUMEN

To elucidate the role of cyclooxygenase-2, we compared the effects of rofecoxib, a selective cyclooxygenase-2 inhibitor, and ibuprofen, a nonselective cyclooxygenase inhibitor, on the evolution of acetic-acid-induced gastric ulcers in rats, evaluating growth factor expression, the angiogenic process, cell proliferation and cell apoptosis. Levels of basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF), angiogenesis and cell proliferation were analysed by immunohistochemical methods, and apoptosis was evaluated by an enzyme immunoassay. Both growth factors and microvessels appeared to be abundant in the granulation tissue of the ulcer bed. Rofecoxib (2.5 mg/kg/day) and ibuprofen (100 mg/kg/day) delayed ulcer healing, but only rofecoxib treatment provoked a reduction of bFGF expression and inhibition of the development of new microvessels. No changes in VEGF expression were detected. Results also showed that proliferation and apoptosis were increased in control ulcerated animals. Rofecoxib reduced significantly both processes. These findings demonstrate that a reduction of bFGF expression and an antiangiogenic action, as well as proliferation/apoptosis inhibition, are some of the mechanisms possibly implicated in the delay in ulcer healing seen after the administration of the highly selective COX-2 inhibitor rofecoxib.


Asunto(s)
Apoptosis/efectos de los fármacos , Inhibidores de la Ciclooxigenasa/farmacología , Lactonas/farmacología , Úlcera Gástrica/prevención & control , Sulfonas/farmacología , Cicatrización de Heridas/efectos de los fármacos , Animales , Antiinflamatorios no Esteroideos/farmacología , Antiinflamatorios no Esteroideos/uso terapéutico , Proliferación Celular/efectos de los fármacos , Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa 2 , Inhibidores de la Ciclooxigenasa/uso terapéutico , Factor 2 de Crecimiento de Fibroblastos/metabolismo , Ibuprofeno/farmacología , Ibuprofeno/uso terapéutico , Inmunohistoquímica , Lactonas/uso terapéutico , Masculino , Neovascularización Fisiológica/efectos de los fármacos , Antígeno Nuclear de Célula en Proliferación/análisis , Prostaglandina-Endoperóxido Sintasas/metabolismo , Ratas , Ratas Wistar , Úlcera Gástrica/etiología , Úlcera Gástrica/metabolismo , Úlcera Gástrica/patología , Sulfonas/uso terapéutico , Factor A de Crecimiento Endotelial Vascular/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...